Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Sarcoma—Clinical Updates: 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Sarcoma—Clinical Updates: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 678

Special Issue Editor

Dr. Julia Visgauss

E-Mail Website
Guest Editor
Department of Orthopaedic Surgery, Duke University, Durham, NC 27710, USA
Interests: orthopedic oncology; bone and soft tissue sarcomas; chondrosarcoma; metastatic sarcoma; limb salvage surgery; pelvic resection; reconstructive surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to the Special Issue "Sarcoma—Clinical Updates: 2nd Edition". This is a new edition; we published five papers in the first volume. For more details, please visit https://www.mdpi.com/journal/jcm/special_issues/P3WPZ1GA0R.

Because of the rarity of these tumors and the wide variety of histologic subtypes, sarcoma has historically been an elusive entity to research. As a result, there have been few clinical advancements in the treatment of sarcoma in the last three decades. However, advanced scientific techniques, improvements in collaborative research, and a focus on histologic-specific investigation has led to exciting recent discoveries, paving the way for improved diagnosis and prognostication in addition to the development of novel therapeutics, such as targeted molecular therapies and immunotherapies. However, more work is still required to understand the patients and tumors which these existing therapies most benefit and how best to further investigate and expand these types of therapeutics to improve outcomes for broader populations of sarcoma patients.

The aim of this Special Issue is to highlight research that improves our understanding of sarcoma biology and prognostication, identify novel biomarkers and/or therapeutic targets, and investigate treatment strategies that improve oncologic and/or functional outcomes. 

Dr. Julia Visgauss
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sarcoma
  • osteosarcoma
  • ewing’s sarcoma
  • chondrosarcoma
  • soft-tissue sarcoma
  • undifferentiated pleo-morphic sarcoma
  • liposarcoma
  • leiomyosarcoma
  • rhabdomyosarcoma
  • metastatic sarcoma
  • targeted molecular therapy
  • immunotherapy
  • orthopedic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2238 KB  
Article
The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients
by Ömer Faruk Kuzu, Nuri Karadurmuş, Nebi Batuhan Kanat, Çağlar Köseoğlu, Ayşegül Dumludağ, Alper Topal, Ramazan Acar, Birol Yıldız, Musa Barış Aykan and İsmail Ertürk
J. Clin. Med. 2025, 14(24), 8621; https://doi.org/10.3390/jcm14248621 - 5 Dec 2025
Viewed by 147
Abstract
Background: Ewing sarcoma (ES) is a highly aggressive malignant tumor that predominantly affects children and young adults. Despite advances in multimodal therapy, relapse and refractory disease remain the leading causes of treatment failure. High-dose chemotherapy followed by autologous stem cell transplantation (HDCT-ASCT) has [...] Read more.
Background: Ewing sarcoma (ES) is a highly aggressive malignant tumor that predominantly affects children and young adults. Despite advances in multimodal therapy, relapse and refractory disease remain the leading causes of treatment failure. High-dose chemotherapy followed by autologous stem cell transplantation (HDCT-ASCT) has been proposed as a consolidation strategy for high-risk or relapsed ES; however, its clinical value remains controversial. Methods: We retrospectively analyzed 46 consecutive patients with locally advanced or metastatic ES who underwent HDCT-ASCT after at least one prior systemic therapy line. Clinical, pathological, and transplant-related variables were evaluated for associations with overall survival (OS), post-transplant OS (OS-2), and progression-free survival (PFS). Survival was estimated using the Kaplan–Meier method, and prognostic factors were assessed by Cox proportional hazards modeling. Results: The median age at diagnosis was 23 years (range: 14–55). Median OS from diagnosis was 42 months, while post-transplant OS-2 and PFS were 8 and 5 months, respectively. Younger patients (≤23 years) had significantly longer OS (50 vs. 34 months; p = 0.027). Liver metastasis predicted inferior OS (HR = 5.411; p = 0.006), whereas lung metastasis was associated with shorter OS-2 (HR = 2.672; p = 0.025) and PFS (HR = 6.037; p = 0.016). Treatment-related mortality was low (2.1%), though hematologic toxicity was universal. Overall, HDCT-ASCT provided transient disease control, with modest benefit confined to younger, chemosensitive, and medically fit patients. Conclusions: In this real-world cohort, HDCT-ASCT was feasible and safe but offered limited survival advantage in heavily pretreated Ewing sarcoma. Prognosis was primarily influenced by age and metastatic distribution, particularly hepatic and pulmonary involvement. These findings support a risk-adapted, biology-driven approach reserving HDCT-ASCT for selected patients and highlight the need for post-transplant maintenance strategies integrating targeted or immunotherapeutic modalities. Full article
(This article belongs to the Special Issue Sarcoma—Clinical Updates: 2nd Edition)
►▼ Show Figures

Figure 1

12 pages, 930 KB  
Article
Chondroblastic Subtype Is Associated with Higher Rates of Local Recurrence in Skeletal Osteosarcoma
by Alexandra N. Krez, Sarah Fagan-Kellogg, Laurie A. Graves, Aron Mebrahtu, Nicole L. Levine, Elizabeth Sachs, William C. Eward, Brian E. Brigman and Julia D. Visgauss
J. Clin. Med. 2025, 14(22), 7952; https://doi.org/10.3390/jcm14227952 - 10 Nov 2025
Viewed by 396
Abstract
Background/Objectives: Locally recurrent osteosarcoma is associated with high patient morbidity and mortality, yet the risk factors for local recurrence remain incompletely understood. Therefore, the objective of this study was to comprehensively assess the impact of tumor histology, patient demographics, surgical resection, and chemotherapy [...] Read more.
Background/Objectives: Locally recurrent osteosarcoma is associated with high patient morbidity and mortality, yet the risk factors for local recurrence remain incompletely understood. Therefore, the objective of this study was to comprehensively assess the impact of tumor histology, patient demographics, surgical resection, and chemotherapy delivery on the risk of local recurrence, development of metastases, and overall patient survival in osteosarcoma. Methods: This single-center retrospective review included 102 patients with skeletal osteosarcoma who underwent primary surgical resection between August 2001 and August 2021. Primary outcomes included the development and timing of local recurrence following primary resection. Data was abstracted from the electronic medical record, and statistical analyses were performed to identify demographic, tumor, or management (surgical and chemotherapy) related factors associated with an increased risk of local recurrence. Results: Locally recurrent osteosarcoma developed in 13.7% (n = 14) of patients after primary resection. Patients with local recurrence were more likely to have the chondroblastic subtype (57.1% versus 19.3% in those without local recurrence, p = 0.005). The chondroblastic subtype was associated with shorter local recurrence-free survival and overall survival than other histologic subtypes (p < 0.001). Resection approach, surgical margin status, histologically assessed response to neoadjuvant chemotherapy, and type and dose intensity of chemotherapy delivered were not statistically associated with risk of local recurrence. Conclusions: Chondroblastic histology is a risk factor for local recurrence in osteosarcoma and is associated with poor overall survival in our patient cohort. Full article
(This article belongs to the Special Issue Sarcoma—Clinical Updates: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop